ArticleBriefings in functional genomics2025
MolEpidPred: a novel computational tool for the molecular epidemiology of foot-and-mouth disease virus using VP1 nucleotide sequence data.
Article in Briefings in functional genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Designing a novel mRNA vaccine against foot-and-mouth disease using immunoinformatics approach.In silico pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Molecular epidemiology of Foot-and-mouth disease (FMD) is crucial to implement its control strategies including vaccination and containment, which primarily deals with knowing serotype, topotype, and lineage of the virus. The existing approaches including serotyping are biological in nature, which are time-consuming and risky due to live virus handling. Thus, novel computational tools are highly required for large-scale molecular epidemiology of the FMD virus. This study reported a comprehensive computational tool for FMD molecular epidemiology. Ten learning algorithms were initially evaluated on cross-validated and ten independent secondary datasets for serotype prediction using sequence-based features through accuracy, sensitivity and 14 other metrics. Next, best performing algorithms, with higher serotype predictive accuracies, were evaluated for topotype and lineage prediction using cross-validation. These algorithms are implemented in the computational tool. Then, performance of the developed approach was assessed on five independent secondary datasets, never seen before, and primary experimental data. Our cross-validated and independent evaluation of learning algorithms for serotype prediction revealed that support vector machine, random forest, XGBoost, and AdaBoost algorithms outperformed others. Then, these four algorithms were evaluated for topotype and lineage prediction, which achieved accuracy ≥96% and precision ≥95% on cross-validated data. These algorithms are implemented in the web-server (https://nifmd-bbf.icar.gov.in/MolEpidPred), which allows rapid molecular epidemiology of FMD virus. The independent validation of the MolEpidPred observed accuracies ≥98%, ≥90%, and ≥ 80% for serotype, topotype, and lineage prediction, respectively. On wet-lab data, the MolEpidPred tool provided results in fewer seconds and achieved accuracies of 100%, 100%, and 96% for serotype, topotype, and lineage prediction, respectively, when benchmarked with phylogenetic analysis. MolEpidPred tool provides an innovative platform for large-scale molecular epidemiology of FMD virus, which is crucial for tracking FMD virus infection and implementing control program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.